Gilead Sciences Is Expanding Aggressively Beyond Traditional Oncology
Gilead Sciences remains one of the strongest revenue generators in oncology cell therapy through its Kite Pharma division.
The company generated nearly USD 29.4 billion in total revenue during 2025, while its oncology and cell therapy business continued expanding globally.
Its CAR-T therapy Yescarta generated approximately USD 1.5 billion in full-year 2025 sales despite rising competition in lymphoma treatment markets. Tecartus added another USD 344 million in annual sales. Total cell therapy revenue reached nearly USD 1.8 billion in 2025.
Gilead also invested heavily in future oncology expansion.
In early 2026, the company announced a deal worth up to USD 7.8 billion to acquire cancer therapy developer Arcellx. The acquisition strengthens Gilead’s next-generation CAR-T pipeline for multiple myeloma and blood cancers.
The company spent nearly USD 5.8 billion on R&D during 2025, showing how aggressively it is investing in oncology innovation.
| Company | 2025 Revenue / Sales Data | Key Oncology & Cell Therapy Highlights |
|---|---|---|
| Gilead Sciences | USD 29.4 Billion total revenue | Yescarta and Tecartus generated nearly USD 1.8 Billion in cell therapy revenue |
| Novartis AG | USD 56.7 Billion total revenue | Kisqali crossed USD 4.78 Billion sales; Kymriah expanded globally |
| Bristol Myers Squibb | USD 48.2 Billion total revenue | Breyanzi and Abecma strengthened CAR-T oncology portfolio |
| Legend Biotech | Carvykti generated USD 1.9 Billion sales | One of the fastest-growing CAR-T therapy companies globally |
| Amgen Inc. | USD 36.8 Billion total revenue | Expanding bispecific T-cell engager and oncology pipeline |
| bluebird bio | Focused on oncology and gene therapies | Continues work in lentiviral gene-modified therapies |
| JW Therapeutics | Expanding commercial CAR-T programs | Developing therapies for lymphoma and leukemia markets |
Novartis AG Continues Building Its CAR-T Leadership
Novartis remains one of the pioneers in commercial CAR-T therapy through Kymriah.
The company generated nearly USD 56.7 billion in total revenue during 2025, placing it among the world’s largest pharmaceutical companies.
Its oncology business delivered strong performance through therapies like Kisqali, Pluvicto, Scemblix, and Kymriah. Kisqali alone crossed USD 4.78 billion in annual sales during 2025, reflecting strong oncology demand globally.
Novartis continues expanding manufacturing facilities across the U.S., Europe, and Asia to improve CAR-T accessibility and reduce treatment timelines.
The company is also investing in radioligand therapy, gene therapy research, and precision oncology platforms to strengthen its long-term cancer treatment portfolio.
Bristol Myers Squibb Is Scaling Up Through Strategic Acquisitions
Bristol Myers Squibb strengthened its oncology cell therapy business through Breyanzi and Abecma.
The company generated approximately USD 48.2 billion in revenue during 2025, making it one of the largest oncology-focused pharmaceutical firms globally.
To strengthen control over Abecma commercialization, Bristol Myers acquired 2seventy bio in a USD 286 million deal during 2025. The acquisition helped the company reduce future profit-sharing costs while expanding its CAR-T market position.
Abecma generated around USD 242 million in U.S. sales during 2025 despite strong competition from newer CAR-T therapies.
The company continues investing heavily in:
- Next-generation CAR-T therapies
- Cell engineering platforms
- Oncology clinical trials
- Automated manufacturing systems
Legend Biotech Emerged as One of the Fastest Growing CAR-T Players
Legend Biotech has rapidly become one of the biggest growth stories in oncology cell therapy through Carvykti.
The company’s CAR-T therapy generated nearly USD 1.9 billion in 2025 sales globally in partnership with Johnson & Johnson.
Industry launch data showed Carvykti becoming one of the fastest-growing CAR-T products in market history.
Quarterly sales jumped from nearly USD 24 million during early launch stages to over USD 524 million by Q3 2025.
The therapy also recorded one of the highest compound annual growth rates among commercial CAR-T products globally.
Legend Biotech is now expanding treatment center networks and manufacturing capabilities to capture rising multiple myeloma demand worldwide.
Amgen and bluebird bio Continue Investing in Advanced Oncology Platforms
Amgen is strengthening its oncology position through bispecific T-cell engager therapies and immuno-oncology research.
The company generated approximately USD 36.8 billion in revenue during 2025 and continues investing in advanced cancer biologics and cell-based therapies.
We’ve brought together 3,000+ insights on pipelines, trends, clinical progress, and competitive data into one simple Cell and Gene Therapy dashboard: https://www.towardshealthcare.com/cell-gene-intelligence-platform
bluebird bio remains focused on gene-modified therapies for hematologic cancers and genetic diseases. Although the company faced commercialization pressure and restructuring challenges, it still maintains strong scientific expertise in lentiviral gene modification technology.
North America Controls Nearly Half of the Global Market
North America dominated the cell and gene therapy for oncology market with a 46% share in 2025.
The region benefits from:
- Strong biotechnology infrastructure
- Advanced cancer hospitals
- High R&D spending
- Faster FDA approvals
- Large-scale clinical trial ecosystems
The United States remains the global center for CAR-T innovation.
More than 2,000 active cell and gene therapy clinical trials are currently running across the country. California, Massachusetts, New York, and Texas have emerged as major oncology biotech hubs.
The FDA’s removal of REMS requirements for several CAR-T therapies during 2025 is expected to improve treatment accessibility and reduce operational burdens for hospitals.
Strong reimbursement systems and rising cancer prevalence continue driving regional market dominance.
Asia Pacific Is Becoming the Fastest Growing Oncology Cell Therapy Market
Asia Pacific captured nearly 21% market share in 2025 and is projected to grow at the fastest CAGR globally over the next decade.
China has become one of the world’s largest CAR-T clinical trial centers, with biotech firms rapidly scaling commercialization programs and manufacturing facilities.
India is also emerging as a major long-term growth engine because of its massive cancer patient pool and improving biotechnology ecosystem.
The country records more than 1.4 million new cancer cases annually, creating strong long-term demand for personalized therapies.
Several factors are accelerating Asia Pacific growth:
- Rising government biotechnology funding
- Expansion of advanced hospital infrastructure
- Increasing foreign biotech investments
- Lower clinical trial costs compared to Western markets
- Growing awareness of precision medicine
Global pharmaceutical companies are increasingly investing in Asia Pacific manufacturing and clinical expansion because the region offers both large patient populations and long-term commercial opportunities.
The next phase of oncology competition may no longer depend only on drug innovation. Manufacturing scale, treatment affordability, and regional accessibility are now becoming the biggest growth drivers in the global cell and gene therapy industry.
About Us
Healthcare WebWire is a sister firm of Towards Healthcare Research and Consulting is a global insights and strategy partner focused on advancing cell and gene therapy innovation. We support biotech firms and healthcare leaders with clinical research expertise, data-driven analytics, and strategic consulting. Our goal is to accelerate the development and delivery of next-generation genetic therapies by transforming complex science into actionable, real-world solutions.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com